Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases.
It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 12, 24 | -1.13 Decreased by -98.25% | -0.83 Decreased by -36.14% |
| Aug 13, 24 | -0.83 Decreased by -167.74% | -0.70 Decreased by -18.57% |
| May 9, 24 | -0.70 Decreased by -37.25% | -0.67 Decreased by -4.48% |
| Mar 21, 24 | -0.61 Increased by +64.94% | -0.82 Increased by +25.61% |
| Nov 7, 23 | -0.57 | -0.76 Increased by +25.00% |
| Aug 7, 23 | -0.31 | -0.72 Increased by +56.94% |
| May 15, 23 | -0.51 | -0.89 Increased by +42.70% |
| Mar 15, 23 | -1.74 | -1.72 Decreased by -1.16% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -56.34 M Decreased by -147.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -41.01 M Decreased by -237.81% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -31.51 M Decreased by -149.90% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -24.39 M Decreased by -168.81% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -22.76 M Decreased by -240.82% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -12.14 M Decreased by -87.39% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.61 M Decreased by -66.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -9.07 M Decreased by -28.10% | Decreased by N/A% Decreased by N/A% |